SEC Form 4 · accession 0001209191-15-074442
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ron Cohen
Officer — President and CEO · Director
Period of report
Oct 2, 2015
Accepted (ET)
Oct 6, 2015 · 8:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 2, 2015 | M | 8,811 | $6.00 | A | 421,211 | D | |
| Common StockF1 | Oct 2, 2015 | M | 70,358 | $5.85 | A | 491,569 | D | |
| Common StockF1 | Oct 2, 2015 | M | 500 | $8.50 | A | 492,069 | D | |
| Common StockF1 | Oct 2, 2015 | M | 54,421 | $15.49 | A | 546,490 | D | |
| Common StockF1,F2 | Oct 2, 2015 | S | 134,090 | $28.0121 | D | 412,400 | D | |
| Common StockF1 | Oct 5, 2015 | M | 910 | $15.49 | A | 413,310 | D | |
| Common StockF1 | Oct 5, 2015 | S | 910 | $30.10 | D | 412,400 | D | |
| Common StockF3 | holding | — | — | — | 100,000 | I | Beneficial Ownership in Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F4 | $6.00 | Oct 2, 2015 | M | 8,811 | D | — | Feb 15, 2016 | Common Stock | 8,811 | 4,005 | D |
| Employee Stock Option (right to buy)F1,F5 | $5.85 | Oct 2, 2015 | M | 70,358 | D | — | Mar 17, 2016 | Common Stock | 70,358 | 14,642 | D |
| Employee Stock Option (right to buy)F1,F6 | $8.50 | Oct 2, 2015 | M | 500 | D | — | Sep 25, 2016 | Common Stock | 500 | 0 | D |
| Employee Stock Option (right to buy)F1,F7 | $15.49 | Oct 2, 2015 | M | 54,421 | D | — | Dec 21, 2016 | Common Stock | 54,421 | 51,673 | D |
| Employee Stock Option (right to buy)F1,F7 | $15.49 | Oct 5, 2015 | M | 910 | D | — | Dec 21, 2016 | Common Stock | 910 | 50,763 | D |
Explanation of responses
- F1Exercises and sales pursuant to a 10b5-1 plan. All of the exercised options were scheduled to expire in 2016 on the expiration dates reported within Table II unless exercised. The reporting person sold the shares resulting from the option exercises with the intent to use the proceeds from those sales primarily to cover the exercise prices of the exercised options as well as to fund tax obligations resulting from the reported transactions and other transactions relating to issuer common stock awards granted to the reporting person.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $28.00 to $28.14 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3These shares were previously reported as directly beneficially owned by the reporting person. On May 28, 2015, the reporting person contributed these shares to a grantor retained annuity trust established by the reporting person. The reporting person is the sole trustee of the grantor retained annuity trust.
- F4The shares subject to these options vested in installments and were fully vested on 2/15/2010.
- F5The shares subject to these options vested in installments and were fully vested on 11/10/2010.
- F6The shares subject to these options vested in installments and were fully vested on 9/25/2010.
- F7The shares subject to these options vested in installments and were fully vested on 1/1/2011.